Incyte (INCY) and Zai Lab (ZLAB) have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an invest
Incyte Corp. said Tuesday it will receive an upfront payment of $17.5 million as part of a license agreement with Zai Lab Ltd. for the development and commercialization of...
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Oil & Gas, Healthcare and Technology sectors led shares higher. At the close in NYSE, the Dow...
Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted for review its supplemental Biologics License Applications (sBLAs) looking for approval of an improved dosing...
Incyte Corporation (NASDAQ:INCY) announced that it is out-licensing the development and commercialization rights to its investigational PD-1 monoclonal antibody, INCMGA0012, in...
Thursday, June 27, 2019The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks,...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Sell||Strong Sell||Strong Buy||Strong Sell||Strong Buy|
|Summary||Strong Sell||Sell||Buy||Neutral||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Inside Up||1M||1||Jun 19|
|Dark Cloud Cover||1D||1||Jul 19, 2019|
|Three Inside Up||1D||2||Jul 18, 2019|
|Three Black Crows||1H||2||Jul 22, 2019 01:00PM|
|Engulfing Bearish||1M||3||Apr 19|
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.